In Response to House Vote on Xylazine Criminalization, Hundreds of Medical Experts, Scientists, Advocates Call for a Public Health Approach
December 13, 2023
December 13, 2023
NEW YORK, Dec. 13 -- The Drug Policy Alliance issued the following news release on Dec. 12, 2023:
Today, Congress passed the SUPPORT Act (H.R. 4531), legislation that includes a provision to permanently place the drug xylazine, also known as tranq, on Schedule III of the Controlled Substances Act (CSA). Despite preliminary scientific research showing that placing xylazine on Schedule III of the CSA is not appropriate, the legislation passed in the House and will now go to the Senate . . .
Today, Congress passed the SUPPORT Act (H.R. 4531), legislation that includes a provision to permanently place the drug xylazine, also known as tranq, on Schedule III of the Controlled Substances Act (CSA). Despite preliminary scientific research showing that placing xylazine on Schedule III of the CSA is not appropriate, the legislation passed in the House and will now go to the Senate . . .